» Articles » PMID: 35445260

Identifying Factors Contributing to Increased Susceptibility to COVID-19 Risk: a Systematic Review of Mendelian Randomization Studies

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2022 Apr 21
PMID 35445260
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To summarize modifiable factors for coronavirus disease 2019 (COVID-19) suggested by Mendelian randomization studies.

Methods: In this systematic review, we searched PubMed, EMBASE and MEDLINE, from inception to 15 November 2021, for Mendelian randomization studies in English. We selected studies that assessed associations of genetically predicted exposures with COVID-19-related outcomes (severity, hospitalization and susceptibility). Risk of bias of the included studies was evaluated based on the consideration of the three main assumptions for instrumental variable analyses.

Results: We identified 700 studies through systematic search, of which 50 Mendelian randomization studies were included. Included studies have explored a wide range of socio-demographic factors, lifestyle attributes, anthropometrics and biomarkers, predisposition to diseases and druggable targets in COVID-19 risk. Mendelian randomization studies suggested that increases in smoking, obesity and inflammatory factors were associated with higher risk of COVID-19. Predisposition to ischaemic stroke, combined bipolar disorder and schizophrenia, attention-deficit and hyperactivity disorder, chronic kidney disease and idiopathic pulmonary fibrosis was potentially associated with higher COVID-19 risk. Druggable targets, such as higher protein expression of histo-blood group ABO system transferase (ABO), interleukin (IL)-6 and lower protein expression of 2'-5' oligoadenylate synthetase 1 (OAS1) were associated with higher risk of COVID-19. There was no strong genetic evidence supporting the role of vitamin D, glycaemic traits and predisposition to cardiometabolic diseases in COVID-19 risk.

Conclusion: This review summarizes modifiable factors for intervention (e.g. smoking, obesity and inflammatory factors) and proteomic signatures (e.g. OAS1 and IL-6) that could help identify drugs for treating COVID-19.

Citing Articles

Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges.

Luo S, Zheng M, Wong V, Au Yeung S eGastroenterology. 2025; 2(4):e100114.

PMID: 39944268 PMC: 11770435. DOI: 10.1136/egastro-2024-100114.


Introduction to Mendelian randomization.

Au Yeung S, Luo S, Iwagami M, Goto A Ann Clin Epidemiol. 2025; 7(1):27-37.

PMID: 39926273 PMC: 11799858. DOI: 10.37737/ace.25004.


Genome-wide Mendelian randomization identifies drugs associated with body height.

Xi L, Cheng R, Zhang M, Pei Z, Ye J, Zhao Z Transl Pediatr. 2024; 13(11):1959-1971.

PMID: 39649642 PMC: 11621899. DOI: 10.21037/tp-24-265.


Adiposity and mortality among intensive care patients with COVID-19 and non-COVID-19 respiratory conditions: a cross-context comparison study in the UK.

Bell J, Carslake D, Hughes A, Tilling K, Dodd J, Doidge J BMC Med. 2024; 22(1):391.

PMID: 39272119 PMC: 11401253. DOI: 10.1186/s12916-024-03598-3.


Higher intraindividual variability of body mass index is associated with elevated risk of COVID-19 related hospitalization and post-COVID conditions.

Yu E, Bravo M, Avelino-Silva V, Bruhn R, Busch M, Custer B Int J Obes (Lond). 2024; 48(12):1711-1719.

PMID: 39134693 PMC: 11674580. DOI: 10.1038/s41366-024-01603-6.


References
1.
Soveg F, Schwerk J, Gokhale N, Cerosaletti K, Smith J, Pairo-Castineira E . Endomembrane targeting of human OAS1 p46 augments antiviral activity. Elife. 2021; 10. PMC: 8357416. DOI: 10.7554/eLife.71047. View

2.
Griffith G, Morris T, Tudball M, Herbert A, Mancano G, Pike L . Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020; 11(1):5749. PMC: 7665028. DOI: 10.1038/s41467-020-19478-2. View

3.
Fan X, Liu Z, Poulsen K, Wu X, Miyata T, Dasarathy S . Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank. Nutrients. 2021; 13(5). PMC: 8152000. DOI: 10.3390/nu13051592. View

4.
Xiao T, Lu J, Zhang J, Johnson R, McKay L, Storm N . A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nat Struct Mol Biol. 2021; 28(2):202-209. PMC: 7895301. DOI: 10.1038/s41594-020-00549-3. View

5.
Burki T . Global COVID-19 vaccine inequity. Lancet Infect Dis. 2021; 21(7):922-923. PMC: 8221728. DOI: 10.1016/S1473-3099(21)00344-3. View